Predictive value of ADAMTS-13 on concealed chronic renal failure in COPD patients

Figures & data

Table 1 Baseline data of included patients

	Non-COPD patients (n=106)	COPD patients (n=106)	Statisticsa	P-value
Age, years	69.27±9.47	69.48±9.15	0.162	0.871
Gender (male proportion)	87.74%	87.74%	0.000	1.000
Smoking percentage	25.47%	88.68%	86.429	<0.001
BMI (kg/cm^2)	22.06±2.95	22.64±3.32	1.346	0.180
ADAMTS-13 (ng/mL)	349.37±31.88	327.59±30.71	5.066	<0.001
vWF (ng/mL)	4.63±1.69	9.22±1.75	19.410	<0.001
MPV (fl)	10.26±0.69	11.82±0.79	15.431	<0.001
PDW (fl)	10.19±1.38	11.01±1.55	4.020	<0.001
Fbg (g/L)	2.50±0.54	4.29±1.60	10.869	<0.001
D-dimer (μg/L)	292.92 (8.83)	295.78 (9.61)	2.228	0.026
IL-6 (pg/mL)	2.11 (1.17)	3.13 (4.12)	3.434	0.001
CRP (mg/L)	2.10 (1.38)	2.64 (4.69)	2.040	0.041
FEV1 (% predicted)	98.26±12.15	54.43±11.27	22.221	<0.001
FEV1 (L)	2.28±0.47	1.67±0.74	7.029	<0.001
FEV1/FVC (%)	76.77±4.05	57.54±9.60	19.009	<0.001
Proportion of concealed CRF	7.55%	19.81%	6.751	0.009

Notes: Data are expressed as n, mean ± SD, median (interquartile range), or n (%), unless otherwise stated.

a Student’s t-test, Wilcoxon rank sum test, or χ² test was used to find the significant difference between the two groups determined by the type of data. Statistical significance (P<0.05) is shown in bold.

Abbreviations: ADAMTS-13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; BMI, body mass index; CRF, chronic renal failure; CRP, C-reactive protein; Fbg, fibrinogen; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; IL-6, interleukin 6; MPV, mean platelet volume; PDW, platelet distribution width; vWF, von Willebrand factor.

Table 2 Univariate logistic regression analysis of concealed CRF

	Normal renal function	Concealed CRF	OR	95% CI	P-value
All subjects
n	183	29
Age, years	69.11±9.47	71.03±8.02	1.024	0.979–1.070	0.302
Gender (male proportion)	86.89%	93.10%	0.491	0.110–2.197	0.352
Smoking percentage	54.64%	72.41%	2.179	0.918–5.173	0.078
BMI (kg/cm^2)	22.31±3.18	22.62±2.95	1.031	0.912–1.167	0.623
ADAMTS-13 (ng/mL)	347.05±25.70	284.40±21.01	0.876	0.834–0.920	<0.001
vWF (ng/mL)	6.63±2.79	8.77±2.67	1.331	1.135–1.560	<0.001
MPV (fl)	10.99±1.10	11.36±0.89	1.374	0.952–1.983	0.090
PDW (fl)	10.60±1.52	10.61±1.54	1.007	0.778–1.302	0.960
Fbg (g/L)	3.16±1.10	4.91±2.49	1.935	1.491–2.512	<0.001
D-dimer (μg/L)	293.70 (7.80)	317.28 (13.12)	1.146	1.097–1.198	<0.001
IL-6 (pg/mL)	2.22 (1.86)	3.04 (3.95)	1.100	0.977–1.239	0.116
CRP (mg/L)	2.07 (1.77)	5.05 (8.02)	1.218	1.102–1.345	<0.001
FEV1 (% predicted)	77.73±26.05	67.59±26.06	0.985	0.971–1.000	0.055
FEV1 (L)	2.00±0.68	1.82±0.75	0.689	0.391–1.213	0.197
FEV1/FVC (%)	67.07±12.26	67.72±11.40	1.005	0.972–1.038	0.785
Proportion of COPD	46.45%	72.41%	3.026	1.275–7.185	0.012
COPD subjects
n	85	21
Age, years	69.13±9.51	70.90±7.56	1.023	0.967–1.082	0.426
Gender (male proportion)	87.06%	90.48%	0.708	0.145–3.468	0.670
Smoking percentage	88.24%	90.48%	1.267	0.256–6.270	0.772
BMI (kg/cm^2)	22.67±3.35	22.52±3.25	0.986	0.853–1.140	0.850
ADAMTS-13 (ng/mL)	337.91±23.22	285.85±20.15	0.891	0.846–0.937	<0.001
vWF (ng/mL)	8.99±1.80	10.14±1.14	1.525	1.105–2.104	0.010
MPV (fl)	11.86±0.80	11.67±0.73	0.730	0.390–1.367	0.325
PDW (fl)	11.02±1.58	10.97±1.48	0.980	0.719–1.337	0.900
Fbg (g/L)	3.93±1.11	5.74±2.35	2.152	1.471–3.149	<0.001
D-dimer (μg/L)	294.38 (7.49)	317.28 (13.12)	1.126	1.071–1.184	<0.001
IL-6 (pg/mL)	3.10 (4.15)	3.19 (4.66)	1.006	0.879–1.151	0.934
CRP (mg/L)	2.22 (2.65)	8.22 (9.17)	1.166	1.055–1.288	0.003
FEV1 (% predicted)	54.14±15.97	55.62±17.79	1.006	0.976–1.036	0.708
FEV1 (L)	1.67±0.73	1.71±0.80	1.080	0.567–2.057	0.815
FEV1/FVC (%)	57.78±9.33	56.57±10.83	0.987	0.941–1.036	1.036

Notes: Data are expressed as n; mean ± SD; median (interquartile range); or n (%), unless otherwise stated. Statistical significance (P<0.05) is shown in bold.

Abbreviations: ADAMTS-13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; BMI, body mass index; CRF, chronic renal failure; CRP, C-reactive protein; Fbg, fibrinogen; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; IL-6, interleukin 6; MPV, mean platelet volume; OR, odds ratio; PDW, platelet distribution width; vWF, von Willebrand factor.

Table 3 Multivariable logistic regression analysis of concealed CRF

	OR	95% CI	P-value
All subjects
ADAMTS-13	0.858	0.795–0.926	<0.001
D-dimer	1.095	1.027–1.169	0.006
CRP	1.252	1.058–1.480	0.009
COPD subjects
ADAMTS-13	0.814	0.702–0.944	0.007
D-dimer	1.141	1.028–1.266	0.013
CRP	1.361	1.050–1.764	0.020

Note: Statistical significance (P<0.05) is shown in bold.

Abbreviations: ADAMTS-13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; CRF, chronic renal failure; CRP, C-reactive protein; OR, odds ratio.

Figure 1 ROC curves for ADAMTS-13 in predicting concealed CRF in COPD patients. The area under the ROC curve was 0.959. Sensitivity and specificity at an ADAMTS-13 cutoff of 318.72 ng/mL were 100% and 81.2%, respectively.

Abbreviations: ADAMTS-13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; CRF, chronic renal failure; ROC, receiver operating characteristic.